Instem (INS)


INS Share PerformanceMore

52 week high328.55 26/09/16
52 week low198.00 25/02/16
52 week change 15.00 (7.54%)
4 week volume53,054 27/01/17

Media for (INS)

Presenter: Phil Reason, CEO

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Instem revenues up 11%

Instem, a leading provider of IT solutions to the global early development healthcare market, says revenues for the year en...

Instem revenues up

Trading Statement

Statement regarding a company’s trading performance (e.g. profit warning)

Instem appoints COO

Instem, a leading provider of IT solutions to the global early development healthcare market, has appointed MaryBeth Tho...

Appointment of Chief Operating Officer

Instem Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017

Phil Reason, CEO of Instem (INS) [LSE:INS] the profitable provider of IT applications and technology enabled services to li...

Growth & Innovation Forum

RNS Number: 5902T Instem plc 09 January 2017 Instem plc ("Instem" or the "Company") Instem plc to exhibit at Growth & Innovation Forum - Tuesday 31 January , London Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market , announces that the Company will be exhibiting at the Growth & Innovation Forum...

Holding(s) in Company

RNS Number: 4127S Instem plc 20 December 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Instem PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or dispo...

Fundamental DataMore

Dividend yield0 %

Equity Research (INS)

progressive research
Instem plc
Instem has published a short trading update for the year to December 2016. The outcome was in line with (and in some areas slightly ahead of) our expectations. The year was impacted by the slowdown...
progressive research
Instem plc
Instem recently confirmed that its Instem Clinical business continues to be impacted by a slowdown in the early-phase clinical market and, despite other areas of Instem performing well, that this...
progressive research
Instem plc
Instem has announced solid interim results. Revenues grew by 21% YoY, accompanied by a 34% improvement in EBITDA. Activity in the pre-clinical segment remains strong, as evidenced by the multi-year...

Latest discussion posts More

  • NEW ARTICLE: Instem worth 24% more

    "I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth A#22 million and demand for its software, which helps drug companies develop commercial drugs ...
    II Editor

Users' HoldingsMore

Users who hold Instem also hold..
RDS 'B'28%

Codes & Symbols